Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Patients younger than 55 years in complete response after two blocks of rituximab and specific intensive chemotherapy will receive four additional blocks of rituximab and attenuated chemotherapy (reduction by 33% of the dose of cyclophosphamide, methotrexate and cytarabine) followed by additional rituximab doses as consolidation. Patients older than 55 years will receive the six blocks with attenuated chemotherapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 years old
Patients diagnosed with de novo mature B-ALL, Burkitt lymphoma (BL). Under physician's criteria, patients with unclassified B-lymphoma with intermediate characteristics between DLBCL and BL could be included.
Candidate to intensive treatment.
You may not be if
Other ALL subtype different from mature B-ALL/BL
Severe complications not due to mature B-ALL/BL (eg, sepsis, pneumonia, shock or hemorrhage) at diagnosis.
Renal failure not due to mature B-ALL /BL
Heart or liver failure
Severe lung disease
Secondary mature B-ALL/BL
Hypersensitivity to foreign proteins
Previous treatment with cytotoxic drugs
Pregnancy/breastfeeding
Severe psychiatric disease
Lack of social or familiar support
Clareo Health | Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
